bullish

Oneness Biotech (4743 TT): Worth of Attention Ahead of Upcoming Key Milestones

368 Views19 Mar 2022 18:15
SUMMARY
  • Oneness Biotech (4743 TT)'s approved drug in Taiwan, Fespixon is the world’s first drug to treat diabetic foot ulcers with superiority in complete wound closure to the standard of care.
  • Fespixon is under review in China, and is under multiple NDA submissions to Asian health authorities. The U.S. phase 3 study is expected to be completed in H1 2023.
  • Key milestones are expected from two other late-stage pipeline drug candidates, FB825 and FB704A in 2022 and beyond.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
x